東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

The Effects of the Biologics Price C...

Addivinola, Frank John, Jr.

FindBook

Google Book

Amazon

博客來

The Effects of the Biologics Price Competition and Innovation Act of 2009 on Biopharmaceutical Research and Development.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	The Effects of the Biologics Price Competition and Innovation Act of 2009 on Biopharmaceutical Research and Development./
作者:	Addivinola, Frank John, Jr.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2018,
面頁冊數:	217 p.
附註:	Source: Dissertations Abstracts International, Volume: 79-11, Section: A.
Contained By:	Dissertations Abstracts International79-11A.
標題:	Intellectual Property. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10791174
ISBN:	9780355856781

The Effects of the Biologics Price Competition and Innovation Act of 2009 on Biopharmaceutical Research and Development.
Addivinola, Frank John, Jr.

The Effects of the Biologics Price Competition and Innovation Act of 2009 on Biopharmaceutical Research and Development. - Ann Arbor : ProQuest Dissertations & Theses, 2018 - 217 p.

Source: Dissertations Abstracts International, Volume: 79-11, Section: A.

Thesis (Ph.D.)--Northeastern University, 2018.

This item must not be sold to any third party vendors.

The biopharmaceutical industry is a significant and rapidly growing sector of the U.S. economy and is critical for tackling many diseases affecting large patient populations. The Biologics Price Competition and Innovation Act (BPCIA) was enacted by Congress in 2009 with the legislative intent to increase innovation and patients' access to biopharmaceuticals by stimulating biotechnology research and development and lowering prices for patients. In this dissertation research, I analyze the impact of the BPCIA and its market exclusivity protections on biopharmaceutical innovation to influence new biological drug development. This study examines how selected indicators of research and development within the biopharmaceutical industry responded to the enactment of the BPCIA. I used published data and compiled time-series analyses to identify major shifts in selected metrics of biopharmaceutical innovation (i.e., indicators) in response to key events (i.e., milestones) associated with the emergence and enactment of the BPCIA. In my data analysis, I measure changes in indicators that mark increases or decreases in innovation activity within biopharmaceutical research and development that may have occurred in response to implementation of the BPCIA. Through this analysis of the BPCIA, I attempt to answer a broader question "Do legislative changes in market exclusivity protection affect innovation in biopharmaceuticals?" Answering this question will address the persistent public policy argument of whether stronger market exclusivity affects innovation and if so, whether the effects are positive or negative. Through interpretation of empirical evidence, my research supports the favorable linking of market exclusivity and encouraging innovation. However, the data analyses also show that biopharmaceutical industry is faced with many regulatory burdens placed by the BPCIA for the development of follow-on biosimilars, which may hinder the opportunities for future cost savings to patients.

ISBN: 9780355856781Subjects--Topical Terms:

782112
Intellectual Property.

The Effects of the Biologics Price Competition and Innovation Act of 2009 on Biopharmaceutical Research and Development.
LDR:03141nmm a2200337 4500 001 2209273
005 20191104073131.5
008 201008s2018 ||||||||||||||||| ||eng d
020 $a 9780355856781
035 $a (MiAaPQ)AAI10791174
035 $a (MiAaPQ)neu:10821
035 $a AAI10791174
040 $a MiAaPQ $c MiAaPQ
100 1 $a Addivinola, Frank John, Jr. $3 3436354
245 1 4 $a The Effects of the Biologics Price Competition and Innovation Act of 2009 on Biopharmaceutical Research and Development.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2018
300 $a 217 p.
500 $a Source: Dissertations Abstracts International, Volume: 79-11, Section: A.
500 $a Publisher info.: Dissertation/Thesis.
500 $a Advisor: Koenig, Thomas H.
502 $a Thesis (Ph.D.)--Northeastern University, 2018.
506 $a This item must not be sold to any third party vendors.
520 $a The biopharmaceutical industry is a significant and rapidly growing sector of the U.S. economy and is critical for tackling many diseases affecting large patient populations. The Biologics Price Competition and Innovation Act (BPCIA) was enacted by Congress in 2009 with the legislative intent to increase innovation and patients' access to biopharmaceuticals by stimulating biotechnology research and development and lowering prices for patients. In this dissertation research, I analyze the impact of the BPCIA and its market exclusivity protections on biopharmaceutical innovation to influence new biological drug development. This study examines how selected indicators of research and development within the biopharmaceutical industry responded to the enactment of the BPCIA. I used published data and compiled time-series analyses to identify major shifts in selected metrics of biopharmaceutical innovation (i.e., indicators) in response to key events (i.e., milestones) associated with the emergence and enactment of the BPCIA. In my data analysis, I measure changes in indicators that mark increases or decreases in innovation activity within biopharmaceutical research and development that may have occurred in response to implementation of the BPCIA. Through this analysis of the BPCIA, I attempt to answer a broader question "Do legislative changes in market exclusivity protection affect innovation in biopharmaceuticals?" Answering this question will address the persistent public policy argument of whether stronger market exclusivity affects innovation and if so, whether the effects are positive or negative. Through interpretation of empirical evidence, my research supports the favorable linking of market exclusivity and encouraging innovation. However, the data analyses also show that biopharmaceutical industry is faced with many regulatory burdens placed by the BPCIA for the development of follow-on biosimilars, which may hinder the opportunities for future cost savings to patients.
590 $a School code: 0160.
650 4 $a Intellectual Property. $3 782112
650 4 $a Public health. $3 534748
650 4 $a Public policy. $3 532803
690 $a 0513
690 $a 0573
690 $a 0630
710 2 $a Northeastern University. $b Law and Public Policy. $3 2098328
773 0 $t Dissertations Abstracts International $g 79-11A.
790 $a 0160
791 $a Ph.D.
792 $a 2018
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10791174